DXCM Dexcom (DXCM) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001093557
Form 144 · 12
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
524
13F, latest reported quarter
What the filings say about DXCM
Insiders, 180 days
-$12.0M net sold
8 sellers · 40% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: purchase, 2025-05-15
Planned sales (Form 144), 90 days
$4.7M
12 notices
Dexcom insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, DEXCOM INC insiders sold a net $12.0M of stock across 394 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 26 earlier Form 4 trades (code P or S) here by this insider (26 sales), the last on Sep 15, 2026.
- The trade is 1.7% of the 98,185 shares held after it.
- 2 other insiders sold within 30 days.
- 524 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP Chief Legal Compliance Off Brown Michael Jon sold about $145.3K of DXCM under a 10b5-1 plan on Oct 15, 2026; 2 other insiders sold within 30 days and 524 funds added in the latest 13F quarter.Context
- 29 earlier Form 4 trades (code P or S) here by this insider (29 sales), the last on Aug 27, 2026.
- The trade is 2.1% of the 123,478 shares held after it.
- 3 other insiders sold within 30 days.
- 524 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP Chief People & Culture Off Stern Sadie sold about $221.0K of DXCM under a 10b5-1 plan on Sep 28, 2026; 3 other insiders sold within 30 days and 524 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Sep 14, 2026.
- The trade is 22.3% of the 29,293 shares held after it.
- 4 other insiders sold within 30 days.
- 524 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director AUGUSTINOS NICHOLAS sold about $549.5K of DXCM under a 10b5-1 plan on Sep 15, 2026; 4 other insiders sold within 30 days and 524 funds added in the latest 13F quarter.Context
- 25 earlier Form 4 trades (code P or S) here by this insider (25 sales), the last on Aug 14, 2026.
- The trade is 1.7% of the 99,885 shares held after it.
- 4 other insiders sold within 30 days.
- 524 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP Chief Legal Compliance Off Brown Michael Jon sold about $142.9K of DXCM under a 10b5-1 plan on Sep 15, 2026; 4 other insiders sold within 30 days and 524 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 16, 2025.
- The trade is 4.3% of the 35,832 shares held after it.
- 4 other insiders sold within 30 days.
- 524 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director AUGUSTINOS NICHOLAS sold about $130.2K of DXCM under a 10b5-1 plan on Sep 14, 2026; 4 other insiders sold within 30 days and 524 funds added in the latest 13F quarter.394 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$12.0M over 180 days
-$4.7M over 90 days
below 89% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
524 funds bought in last quarter
more than 95% of Medical Devices
Revenue
+15.6% year over year
more than 62% of Medical Devices
Margin
17.9% net margin
more than 91% of Medical Devices
Buybacks
$603.6M repurchased, FY to 2026-06-30
more than 92% of Medical Devices
Short interest
3.7% of the float short (float per yahoo 2026-10-26) · 3.2 days to cover · settled 2026-09-30
more than 53% of Medical Devices
What changed in the last 30 days
Oct 19EVP Chief Legal Compliance Off Brown Michael Jon sold $145.3K under a 10b5-1 plan (Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 15Officer MICHAEL BROWN filed to sell $145.3K by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Sep 30EVP Chief People & Culture Off Stern Sadie sold $221.0K under a 10b5-1 plan (Sep 28)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 28Officer SADIE STERN filed to sell $221.0K by Sep 28 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch DXCM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+10.2%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns DXCM: institutional holders (13F)
13F holdings, latest reported quarter
38,244,137 sh
$2.6B
25,209,752 sh
$1.7B
19,656,540 sh
$1.3B
18,380,806 sh
$1.2B
15,288,133 sh
$1.0B
Congress trades in DXCM
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2025-05-15 · disclosed 25 days later
$1,001 - $15,000
Sold 2025-05-12 · disclosed 41 days later
$15,001 - $50,000
Bought 2025-05-08 · disclosed 45 days later
$15,001 - $50,000
Sold 2025-04-08 · disclosed 20 days later
$1,001 - $15,000
Sold 2025-04-07 · disclosed 31 days later
$15,001 - $50,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
DXCM planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
MICHAEL BROWN
Filed 2026-10-15
$145.3K
SADIE STERN
Filed 2026-09-28
$221.0K
AUGUSTINOS NICHOLAS
Filed 2026-09-15
$549.5K
MICHAEL BROWN
Filed 2026-09-15
$142.9K
AUGUSTINOS NICHOLAS
Filed 2026-09-14
$130.2K
DXCM mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Motley Fool Mid-Cap Growth ETF
$6.0M position · as of 2026-05-31
5.2%
Global X HealthTech ETF
$1.2M position · as of 2026-05-31
4.9%
Global X Internet of Things ETF
$11.9M position · as of 2026-05-31
4.7%
iShares U.S. Medical Devices ETF
$121.7M position · as of 2026-06-30
4.0%
Virtus KAR Health Sciences Fund
$2.8M position · as of 2026-06-30
3.0%
MIG Core ETF
$22.3M position · as of 2026-05-31
2.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 5 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
1 active
1
Phase 4
1 active
5
Not applicable
3 active
What changed recently
Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom
2026-09-03 · Recruiting → Active Not Recruiting
,
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Kevin Sayer
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$15.8M
-$8.7M
$5.6M
-16%
-21%
2023
$15.7M
$23.0M
$5.0M
+34%
-25%
2022
$15.4M
$5.7M
$4.4M
+23%
-21%
2021
$12.0M
$36.1M
$5.0M
+45%
+4%
2020
$13.8M
$45.1M
$5.7M
+69%
+33%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $12.0M sold by insiders over 180 days, 524 funds added last quarter, $4.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
DXCM financials
Revenue growth
+15.6%
XBRL, annual
Net margin
17.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$5.0B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM DXCM
| FY Dec 2025 | $4.7B |
| FY Dec 2024 | $4.0B |
| FY Dec 2023 | $3.6B |
| FY Dec 2022 | $2.9B |
| FY Dec 2021 | $2.4B |
| Jun 2026 | $1.3B |
| Mar 2026 | $1.2B |
| Dec 2025 | $1.3B |
| Sep 2025 | $1.2B |
| Jun 2025 | $1.2B |
| Mar 2025 | $1.0B |
| Dec 2024 | $1.1B |
| Sep 2024 | $994.2M |
At each fiscal year end
Single quarter
Net margin, TTM
+20.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM DXCM
| FY Dec 2025 | +17.9% |
| FY Dec 2024 | +14.3% |
| FY Dec 2023 | +14.9% |
| FY Dec 2022 | +11.7% |
| FY Dec 2021 | +8.9% |
| Jun 2026 | +19.0% |
| Mar 2026 | +16.7% |
| Dec 2025 | +21.2% |
| Sep 2025 | +23.5% |
| Jun 2025 | +15.5% |
| Mar 2025 | +10.2% |
| Dec 2024 | +13.6% |
| Sep 2024 | +13.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.4B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM DXCM
| FY Dec 2025 | $1.1B |
| FY Dec 2024 | $630.7M |
| FY Dec 2023 | $511.9M |
| FY Dec 2022 | $304.7M |
| FY Dec 2021 | $53.3M |
| Jun 2026 | $184.5M |
| Mar 2026 | $449.0M |
| Dec 2025 | $192.1M |
| Sep 2025 | $579.4M |
| Jun 2025 | $208.9M |
| Mar 2025 | $96.8M |
| Dec 2024 | $176.8M |
| Sep 2024 | $88.3M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity DXCM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt DXCM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+38.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity DXCM
| FY Dec 2025 | +34.5% |
| FY Dec 2024 | +27.6% |
| FY Dec 2023 | +25.8% |
| FY Dec 2022 | +16.3% |
| FY Dec 2021 | +12.1% |
| Jun 2026 | +38.5% |
| Mar 2026 | +35.6% |
| Dec 2025 | +34.5% |
| Sep 2025 | +30.6% |
| Jun 2025 | +22.8% |
| Mar 2025 | +23.7% |
| Dec 2024 | +27.6% |
| Sep 2024 | +32.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+14.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets DXCM
| FY Dec 2025 | +13.0% |
| FY Dec 2024 | +9.0% |
| FY Dec 2023 | +9.3% |
| FY Dec 2022 | +6.6% |
| FY Dec 2021 | +4.7% |
| Jun 2026 | +14.5% |
| Mar 2026 | +13.9% |
| Dec 2025 | +13.0% |
| Sep 2025 | +10.4% |
| Jun 2025 | +8.1% |
| Mar 2025 | +8.1% |
| Dec 2024 | +9.0% |
| Sep 2024 | +10.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
no debt line filed
Return on invested capital DXCM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+28.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed DXCM
| FY Dec 2025 | +23.5% |
| FY Dec 2024 | +14.5% |
| FY Dec 2023 | +14.5% |
| FY Dec 2022 | +10.1% |
| FY Dec 2021 | +6.7% |
| Jun 2026 | +28.1% |
| Mar 2026 | +25.4% |
| Dec 2025 | +23.5% |
| Sep 2025 | +17.7% |
| Jun 2025 | +15.1% |
| Mar 2025 | +14.7% |
| Dec 2024 | +14.5% |
| Sep 2024 | +13.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
30.93x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing DXCM
| FY Dec 2025 | 31.76x |
| FY Dec 2024 | 54.38x |
| FY Dec 2023 | 95.45x |
| FY Dec 2022 | 139.80x |
| FY Dec 2021 | 141.30x |
| Jun 2026 | 26.73x |
| Mar 2026 | 26.95x |
| Dec 2025 | 31.76x |
| Sep 2025 | 37.38x |
| Jun 2025 | 60.62x |
| Mar 2025 | 50.96x |
| Dec 2024 | 54.38x |
| Sep 2024 | 40.39x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value DXCM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.8%
TTM free cash flow over market value at close 2026-10-23
FCF yield DXCM
| FY Dec 2025 | +4.2% |
| FY Dec 2024 | +2.1% |
| FY Dec 2023 | +1.1% |
| FY Dec 2022 | +0.7% |
| FY Dec 2021 | +0.4% |
| Jun 2026 | +5.4% |
| Mar 2026 | +5.9% |
| Dec 2025 | +4.2% |
| Sep 2025 | +4.0% |
| Jun 2025 | +1.7% |
| Mar 2025 | +2.2% |
| Dec 2024 | +2.1% |
| Sep 2024 | +2.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.41x
P/E over trailing EPS growth of 75%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing DXCM
| FY Dec 2025 | 0.69x |
| FY Dec 2024 | 5.44x |
| FY Dec 2023 | 1.58x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.36x |
| Mar 2026 | 0.36x |
| Dec 2025 | 0.69x |
| Sep 2025 | 4.43x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 5.44x |
| Sep 2024 | 0.49x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $4.7B | $4.0B | $3.6B | $2.9B |
| Gross profit | $2.8B | $2.4B | $2.3B | $1.9B |
| Operating income | $911.8M | $600.0M | $597.7M | $391.2M |
| Net income | $836.3M | $576.2M | $541.5M | $341.2M |
| EPS (diluted) | 2.09 | 1.42 | 1.30 | 0.82 |
| Operating cash flow | $1.4B | $989.5M | $748.5M | $669.5M |
| Cash | $917.7M | $606.1M | $566.3M | $642.3M |
| Buybacks | $500.0M | $750.0M | $688.7M | $557.7M |
SEC XBRL, fiscal years, as known on 2026-10-27
DXCM Stock Sonar score 5/7 axes
Find similar shapesCompareDXCM ranks highest on profitability (96th percentile) and institutional and government (95th), and lowest on insider conviction (7th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
DXCM filings, in plain words
Are Dexcom insiders buying or selling DXCM?
In the 180 days to 2026-10-27, Dexcom insiders were net sellers, a net $12.0M across purchases and sales reported on Form 4, by 8 sellers.
Have members of Congress traded DXCM?
Yes, but not in the year to 2026-10-27; the latest on record is a purchase by Rob Bresnahan dated 2025-05-15.
Are there planned insider sales of DXCM?
Yes. 12 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $4.7M of stock; the latest, by MICHAEL BROWN, was filed 2026-10-15.
Read the full summary
In the 180 days to 2026-10-27, Dexcom insiders were net sellers of DXCM, a net $12.0M across purchases and sales reported on Form 4 by 8 sellers. 40% of the 25 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Members of Congress have disclosed trades in DXCM, none in the last year; the latest on record is a purchase by Rob Bresnahan dated 2025-05-15. Insiders filed 12 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $4.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
